the e19a2 transcript. These abnormalities were associated with less favorable clinical courses, with a median survival probability projected at 37 or 190 months for those with or without additional abnormalities, respectively. 3, 4 Furthermore, some of these cases presented initially as CML in transformation or as acute myeloid leukemia. Our case also had an additional chromosomal abnormality (del(9)(p22), À13) at the time of diagnosis. These reports and our case suggest that the presence of the e19a2 transcript, especially in cases showing additional chromosomal abnormalities, might be associated with presentation of more aggressive phenotypes or disease progression.
According to the few available reports on imatinib treatment in CML patients with the e19a2 transcript, imatinib induces hematological, cytogenetic or molecular responses. 4, 6 Previously, we also reported that imatinib could induce complete cytogenetic response in three CML patients with the e19a2 transcript (two chronic phases, one myeloid blastic crisis). 6 In the present case, imatinib in combination with conventional chemotherapy served as a good bridge to unrelated donor transplantation in terms of hematological, cytogenetic and molecular responses. These reports and our case suggest that imatinib may be valuable for e19a2-positive CML as well as Ph-positive ALL. Some recent case reports have suggested that the emergence of a BCR-ABL1 kinase domain mutation (for example, Y253H, E355G) induces imatinib resistance in e19a2-positive CML patients. 7, 8 Thus, more studies are warranted in order to further illustrate the influence of the e19a2 transcript on clinical features at presentation, progression of the disease and response to imatinib therapy.
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The authors declare no conflict of interest. The current World Health Organization (WHO) classification of hematological malignancies includes a number of entities defined by specific genetic abnormalities. Most known abnormalities result from chromosomal translocations and mutations involving genes encoding transcription factors or tyrosine kinases. We report here the finding of activation of a novel palmitoyltransferase ZDHHC14 through the chromosomal Letters to the Editor translocation t(6;14)(q25;q32) in patients with acute biphenotypic leukemia. Biphenotypic leukemia refers to a single population of leukemic blasts co-expressing antigens of both lymphoid and myeloid lineages. It is difficult to diagnose, with no specific genetic lesion identified as a diagnostic marker. It is also difficult to treat, as many cases are resistant to chemotherapy. Based on the lineage specificity of co-expressed antigens, biphenotypic leukemia can be further classified into B/myeloid and T/myeloid. Although the molecular basis of biphenotypic leukemia is largely unknown, a recurrent chromosomal translocation, t(6;14)(q25;q32), has been documented in biphenotypic leukemia in two children 1,2 and two adults. 3 This translocation has not been characterized at the molecular level. We recently identified this same chromosomal translocation in two additional individuals with T/myeloid leukemia. The first patient was a 17-year-old boy diagnosed with T/myeloid leukemia based on co-expression of the T-cell markers CD2, cytoplasmic CD3 (cCD3) and CD7, and the myeloid markers CD13 and CD117, as well as CD38 and HLA-DR. Initial karyotype analysis indicated an abnormality involving 6q. Subsequent fluorescence in-situ hybridization (FISH) analysis revealed a t(6;14)(q25;q32). The second patient was an 11-year-old boy with T/myeloid leukemia co-expressing CD2, cCD3, CD7, CD13, CD33, CD34, CD58 and CD117. To look for subtle loss or gain of genomic fragments at the translocation breakpoints or elsewhere in the genome, we scanned the genomes of both patients using an array-based comparative genomic hybridization platform, the Agilent 244 K whole-genome array chip (http://www.agilent. com/chem/goCGH). Although polymorphic copy number variations previously identified in healthy individuals (database of genomic variants) were observed in each patient, no consistent genomic imbalance was detected. Special attention was given to the translocation breakpoints, but no significant gain or loss of DNA was appreciated in either patient. Thus, the t(6;14) was genomically balanced in both patients.
Balanced chromosomal translocations typically juxtapose two previously unlinked segments of the genome and result in either deregulated expression of oncogenes or formation of novel fusion genes. Cloning and characterization of chromosomal translocations, especially in hematological malignancies, has been one of the most efficient approaches to discovering previously unknown genes with important biological functions. In order to delineate the molecular basis of the t(6;14) in biphenotypic leukemia, we used a series of BAC clones as FISH probes to determine the translocation breakpoints on 6q and 14q in blasts from both of our patients, and narrowed down the 6q breakpoints in both patients to a single BAC clone, RP11-446N2 (Figures 1a and b) . According to the current version of the human genome map, no known genes have been found in the DNA sequence represented by this BAC clone. FISH mapping of the 14q breakpoints, on the other hand, revealed the translocation breakpoints in the two patients to be 500 kb apart ( Figure 1a ). This region is downstream of BCL11B, a member of the Kruppel family of zinc finger transcription factors that is universally expressed during T-cell differentiation. This genomic region has been known as a 'genomic desert', owing to the lack of protein-coding genes. However, multiple regulatory elements have been identified within this region. Significantly, these elements have been reported to be responsible for the transcriptional activation of a homeobox gene, TLX3 (also known as HOX11L2), as a result of a cryptic translocation Figure 1 Detection of a chromosomal translocation involving 6q and 14q. (a) Schematic presentation of breakpoints associated with t(6;14) rearrangements. Transcription orientation is indicated by arrows. The breakpoints on 6q in blasts from both patients are within BAC clone RP11-446N2. The breakpoints on 14q are within RP11-49D24 for patient 1 and within RP11-431B1 for patient 2. In both cases the regulatory elements downstream of BCL11B were translocated upstream of the indicated three genes on 6q, including ZDHHC14. (b) FISH with BAC clone RP11-446N2 on a metaphase with t(6;14). A centromere probe (green) was used to identify both copies of chromosome 6. The BAC probe (red) hybridized to its expected target of 6q25 and the translocation partner 14q32, demonstrating that the translocation breakpoint lies within the DNA sequences found in this BAC clone. (c) Quantitative real time RT-PCR analysis of gene expression of the three genes flanking the 6q breakpoint. Induction ratios of each gene (fold change) by t(6;14) were calculated using expression level, normalized to expression level of the control gene GAPDH. Experiments were performed in triplicate (n ¼ 3) and error bars indicate s.d. ARID1B, AT-rich interactive domain 1B, SWI1-like; SNX9, Sorting nexin 9, which may be involved in intracellular trafficking; ZDHHC14, zinc finger DHHC-type containing 14. t(5;14) in T-cell acute lymphoblastic leukemia. 4, 5 These findings led us to speculate that the same transcriptional regulatory region might have activated a target gene in 6q25 with an important role in the development of T/myeloid leukemia.
With reference to the genome map, the t(6;14) resulted in juxtaposition of the regulatory region of 14q32 to 6q25. The first three genes in 6q25 that were downstream of the regulatory region from 14q32 are indicated in Figure 1a . Using quantitative real-time RT-PCR analysis, we analyzed the transcription levels of these three genes in the available paired leukemic and non-leukemic bone marrow samples from the second patient. The leukemic sample was obtained at the time of diagnosis, when t(6;14) was present in approximately 90% of the cells. The non-leukemic sample was obtained during his clinical remission, with no detectable t(6;14). All three genes exhibited increased expression in the leukemic sample, with ZDHHC14 upregulated more than 15-fold (Figure 1c 0 . We then performed western blot analysis using an anti-ZDHHC14 antibody (Abcam) to measure and compare ZDHHC14 protein levels in normal peripheral blood-derived CD34 þ cells and lineage-committed CD14 þ (monocytes), CD2 þ (T cells), CD19 þ (B cells), and the leukemia cell lines K562 and U937. K562 is a leukemia progenitor line established from a patient with chronic myeloid leukemia (CML) in blast crisis. This cell line bears some proteomic resemblance to both undifferentiated granulocytes and erythrocytes. U937 was established from a diffuse histiocytic lymphoma and displays many monocytic characteristics. ZDHHC14 protein was not detected in any subpopulation of normal blood cells (Figure 2 ), but the 53 kDa protein was detected in both K562 and U937 cells. We extended our analysis to measure ZDHHC14 expression in bone marrow samples from two additional patients with T/myeloid leukemia as well as patients with various subtypes of acute leukemia. ZDHHC14 protein was not detectable in an AML with t(8;21), two AMLs with t(15;17), an AML with inv(16) and a B-cell acute lymphoblastic leukemia with t(12;21). These subtypes of leukemia are considered to have favorable prognosis. The protein was barely detectable in a CML sample. However, increased expression of ZDHHC14 was evident in samples from two patients with T/myeloid leukemia, two AML patients with FLT3 mutations and two AML patients with complex karyotypes (Figure 2) . These features are known to be associated with unfavorable prognosis.
ZDHHC14 is an evolutionarily conserved gene. Although it remains to be characterized in mammals, its Drosophila homolog (termed Approximated) has recently been found to be a DHHC palmitoyltransferase involved in the regulation of Fat signaling. 6 Fat is a Drosophila tumor suppressor gene, encoding a large cadherin that regulates growth and a form of tissue organization known as planar cell polarity. Protein palmitoylation is a classical and reversible lipid modification that has been shown to regulate protein stability and intracellular localization, as well as protein-protein and protein-lipid interactions. The reversible nature of this post-translational modification allows proteins to shuttle between intracellular compartments or re-localize in physiological contexts. Although the role of protein palmitoylation in hematopoiesis is currently unknown, recent studies in neuronal development have demonstrated that palmitoylation regulates diverse aspects of neuronal protein trafficking and function. 7 Considering that inhibition of differentiation is an early and essential step in leukemogenesis, we sought to determine the potential regulatory role of ZDHHC14 in cellular differentiation. The leukemia progenitor cell line K562 is an established in vitro model for the study of hematopoietic differentiation. Upon exposure to 12-O-tetradecanoylphorbol-13-acetate (TPA), K562 cells can be induced to undergo megakaryocytic differentiation, as indicated by expression of megakaryocytic marker CD61. Using this model, we performed transfection experiments to overexpress ZDHHC14 in K526 cells. A mammalian expression vector with a CMV promoter was constructed to carry a ZDHHC14-GFP fusion protein Ohno et al. 8 have cloned all yeast and human DHHCcontaining palmitoylating enzymes and examined their intracellular localization and tissue-specific expression. Each of these proteins was found to exhibit a distinguishing localization (endoplasmic reticulum (ER), Golgi, vacuole or plasma membrane) and tissue distribution. ZDHHC14 was reported to be enriched in the ER. Its mRNA was expressed in various tissues, with expression levels being high in the liver and testis and low in leukocytes. We found that the ZDHHC14 protein was not detected in subpopulations of leukocytes from normal peripheral blood. The increased expression of this protein in biphenotypic leukemia, in subsets of AML with unfavorable prognosis and in leukemia progenitor cell lines suggests that the increased expression of ZDHHC14 may be associated with a primitive status of leukocytes. Further characterization of this protein will help to delineate its regulatory function in dynamic protein palmitoylation and protein shuttling, and its potential interactions with signaling pathways regulating hematopoiesis and leukemogenesis.
In summary, we report overexpression of a previously uncharacterized palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and subsets of acute myeloid leukemia with unfavorable prognostic features. We also provided evidence that overexpression of ZDHHC14 inhibits cellular differentiation. These findings suggest that palmitoyltransferase has a previously unappreciated role in leukemia. Further characterization of ZDHHC14 may broaden our knowledge of leukemogenesis, contribute to risk stratification of acute leukemia and provide a novel therapeutic target for the treatment of subsets of leukemia. The recent World Health Organization (WHO) classification clearly defined a new entity, named 'myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1', as a category of three rare specific but related disease groups. 1 They are characterized by the formation of a fusion gene encoding an aberrant tyrosine kinase and almost always associated with peripheral blood eosinophilia. 1 Myeloid and lymphoid neoplasms with PDGFRA rearrangement are unique disease entities mostly characterized by the formation of a fusion gene FIP1L1-PDGFRA, as a result of a cryptic deletion at chromosome 4q12. 1, 2 The disease presents generally as chronic eosinophilic leukemia but can also present as acute myeloid leukemia, T-lymphoblastic lymphoma or both simultaneously. Although the hematopoietic stem cell has been postulated as a possible cellular origin of the disease, clinical manifestations are apparently limited only to the myeloid and T-cell lineages both in chronic phase and in acute leukemic transformation. 1, 2 In this study we present an extremely rare case, in which a single genetic abnormality (PDGFRA rearrangement) led to multiple morphologically and immunophenotypically distinct diseases, including T-lymphoblastic lymphoma, a myeloproliferative neoplasm with eosinophilia and abnormal mastocytosis, and a precursor B-cell acute lymphoblastic leukemia, thus involving all three major hematopoietic lineages, that is, myeloid, T-cell and B-cell in the same patient, truly representing a 'pluripotent hematopoietic stem cell disorder. ' The patient was a 42-year-old Filipino male who had a reported long history of persistent eosinophilia and was evaluated and followed at an outside hospital, but no treatment was given. In October 2008, the patient was found to have a right axillary mass/enlarged lymph node and was subsequently biopsied at that hospital, which revealed a 'T/NK cell lymphoma'. The patient received four cycles of CHOP-based chemotherapy after the initial diagnosis. In November 2008, the patient was transferred to the City of Hope National Medical Center (COHNMC) for further management. The outside axillary mass biopsy was reviewed at COHNMC and additional immunohistochemical studies were performed. The biopsy demonstrated involvement of the T-cell lymphoblastic lymphoma in the axillary lymph node. The diagnosis was confirmed by immunohistochemical studies showing that the tumor cells were positive for CD3 and TdT, and aberrant double positive for CD4 and CD8 but completely negative for B-cell or myeloid cell antigens (Figures 1a-c) . At the time of admission to COHNMC, the patient had marked leukocytosis, eosinophilia and anemia with a white blood cell count of 24.6 K/ml, with 65% circulating eosinophils, a hemoglobin of 10.6 g per 100 ml, and platelets of 199 K/ml. A bone marrow biopsy was performed and revealed a hypercellular marrow with features consistent with myeloproliferative neoplasm with marked eosinophilia and abnormal accumulation of marrow neoplastic mast cells (Figures 1c,d,f) . Conventional cytogenetic analysis demonstrated a normal male chromosomal karyotype 46 X;Y and further molecular analysis yielded no evidence of BCR/ABL transcripts or JAK-2 V617F mutation. On the basis of the clinical manifestation of combined peripheral blood eosinophilia, bone marrow myeloproliferative disorder and T-cell lymphoblastic lymphoma in the axillary mass of the patient, we entertained the possibility of a newly recognized entity in the 2008 WHO classification as 'myeloid and lymphoid neoplasms with PDGFRA rearrangement'. Therefore, we performed cytogenetic and molecular studies and found that CHIC2 gene deletion (a marker of indicating FIP1LI-PDGFRA translocation) was clearly identified by florescence in situ hybridization in both the bone marrow biopsy (47%) and axillary mass biopsy (81%) specimens, respectively, indicating the presence of FIP1L1-PDGFRA translocation in neoplastic myeloid and T-lymphoid cells of both lesions, providing strong evidence to support the diagnosis. The patient was subsequently treated with Dasatinib at the dose of 100 mg daily and followed by 70 mg twice a day, and showed a good response with evidence of continued decrease in total white blood cell counts and peripheral blood eosinophilia.
